122 related articles for article (PubMed ID: 8824549)
1. Cell proliferation and apoptosis during prostatic tumor xenograft involution and regrowth after castration.
Bladou F; Vessella RL; Buhler KR; Ellis WJ; True LD; Lange PH
Int J Cancer; 1996 Sep; 67(6):785-90. PubMed ID: 8824549
[TBL] [Abstract][Full Text] [Related]
2. Molecular profile of androgen-independent prostate cancer xenograft LuCaP 23.1.
Fina F; Muracciole X; Rocchi P; Nanni-Métellus I; Delfino C; Daniel L; Dussert C; Ouafik L'; Martin PM
J Steroid Biochem Mol Biol; 2005 Sep; 96(5):355-65. PubMed ID: 16043352
[TBL] [Abstract][Full Text] [Related]
3. Androgen withdrawal inhibits tumor growth and is associated with decrease in angiogenesis and VEGF expression in androgen-independent CWR22Rv1 human prostate cancer model.
Cheng L; Zhang S; Sweeney CJ; Kao C; Gardner TA; Eble JN
Anticancer Res; 2004; 24(4):2135-40. PubMed ID: 15330153
[TBL] [Abstract][Full Text] [Related]
4. Characterization of a novel androgen-sensitive, prostate-specific antigen-producing prostatic carcinoma xenograft: LuCaP 23.
Ellis WJ; Vessella RL; Buhler KR; Bladou F; True LD; Bigler SA; Curtis D; Lange PH
Clin Cancer Res; 1996 Jun; 2(6):1039-48. PubMed ID: 9816265
[TBL] [Abstract][Full Text] [Related]
5. Molecular analysis integrating different pathways associated with androgen-independent progression in LuCaP 23.1 xenograft.
Rocchi P; Muracciole X; Fina F; Mulholland DJ; Karsenty G; Palmari J; Ouafik L; Bladou F; Martin PM
Oncogene; 2004 Dec; 23(56):9111-9. PubMed ID: 15489889
[TBL] [Abstract][Full Text] [Related]
6. Prostatic tumor regrowth after initially successful castration therapy may be related to a decreased apoptotic cell death rate.
Landström M; Damber JE; Bergh A
Cancer Res; 1994 Aug; 54(16):4281-4. PubMed ID: 7913874
[TBL] [Abstract][Full Text] [Related]
7. NE-10 neuroendocrine cancer promotes the LNCaP xenograft growth in castrated mice.
Jin RJ; Wang Y; Masumori N; Ishii K; Tsukamoto T; Shappell SB; Hayward SW; Kasper S; Matusik RJ
Cancer Res; 2004 Aug; 64(15):5489-95. PubMed ID: 15289359
[TBL] [Abstract][Full Text] [Related]
8. Apoptosis levels increase after castration in the CWR22 human prostate cancer xenograft.
Smitherman AB; Gregory CW; Mohler JL
Prostate; 2003 Sep; 57(1):24-31. PubMed ID: 12886520
[TBL] [Abstract][Full Text] [Related]
9. LuCaP 35: a new model of prostate cancer progression to androgen independence.
Corey E; Quinn JE; Buhler KR; Nelson PS; Macoska JA; True LD; Vessella RL
Prostate; 2003 Jun; 55(4):239-46. PubMed ID: 12712403
[TBL] [Abstract][Full Text] [Related]
10. Androgen receptor expression and cellular proliferation during transition from androgen-dependent to recurrent growth after castration in the CWR22 prostate cancer xenograft.
Kim D; Gregory CW; French FS; Smith GJ; Mohler JL
Am J Pathol; 2002 Jan; 160(1):219-26. PubMed ID: 11786415
[TBL] [Abstract][Full Text] [Related]
11. Serum prostate specific antigen levels in mice bearing human prostate LNCaP tumors are determined by tumor volume and endocrine and growth factors.
Gleave ME; Hsieh JT; Wu HC; von Eschenbach AC; Chung LW
Cancer Res; 1992 Mar; 52(6):1598-605. PubMed ID: 1371718
[TBL] [Abstract][Full Text] [Related]
12. A metastatic and androgen-sensitive human prostate cancer model using intraprostatic inoculation of LNCaP cells in SCID mice.
Sato N; Gleave ME; Bruchovsky N; Rennie PS; Beraldi E; Sullivan LD
Cancer Res; 1997 Apr; 57(8):1584-9. PubMed ID: 9108464
[TBL] [Abstract][Full Text] [Related]
13. The suppression of human prostate tumor growth in mice by the intratumoral injection of a slow-release polymeric paste formulation of paclitaxel.
Jackson JK; Gleave ME; Yago V; Beraldi E; Hunter WL; Burt HM
Cancer Res; 2000 Aug; 60(15):4146-51. PubMed ID: 10945622
[TBL] [Abstract][Full Text] [Related]
14. Androgen receptor regulation of G1 cyclin and cyclin-dependent kinase function in the CWR22 human prostate cancer xenograft.
Gregory CW; Johnson RT; Presnell SC; Mohler JL; French FS
J Androl; 2001; 22(4):537-48. PubMed ID: 11451350
[TBL] [Abstract][Full Text] [Related]
15. Prostatic cell lineage markers: emergence of BCL2+ cells of human prostate cancer xenograft LuCaP 23 following castration.
Liu AY; Corey E; Bladou F; Lange PH; Vessella RL
Int J Cancer; 1996 Jan; 65(1):85-9. PubMed ID: 8543402
[TBL] [Abstract][Full Text] [Related]
16. Enhanced androgen receptor signaling correlates with the androgen-refractory growth in a newly established MDA PCa 2b-hr human prostate cancer cell subline.
Hara T; Nakamura K; Araki H; Kusaka M; Yamaoka M
Cancer Res; 2003 Sep; 63(17):5622-8. PubMed ID: 14500404
[TBL] [Abstract][Full Text] [Related]
17. Progression to androgen independence is delayed by adjuvant treatment with antisense Bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model.
Gleave M; Tolcher A; Miyake H; Nelson C; Brown B; Beraldi E; Goldie J
Clin Cancer Res; 1999 Oct; 5(10):2891-8. PubMed ID: 10537358
[TBL] [Abstract][Full Text] [Related]
18. Molecular correlates of bcl-2-enhanced growth following androgen-ablation in prostate carcinoma cells in vivo.
Beham AW; Sarkiss M; Brisbay S; Tu SM; von Eschenbach AC; McDonnell TJ
Int J Mol Med; 1998 Jun; 1(6):953-9. PubMed ID: 9852630
[TBL] [Abstract][Full Text] [Related]
19. Quantitation of apoptotic activity following castration in human prostatic tissue in vivo.
Staack A; Kassis AP; Olshen A; Wang Y; Wu D; Carroll PR; Grossfeld GD; Cunha GR; Hayward SW
Prostate; 2003 Feb; 54(3):212-9. PubMed ID: 12518326
[TBL] [Abstract][Full Text] [Related]
20. Increased Hsp27 after androgen ablation facilitates androgen-independent progression in prostate cancer via signal transducers and activators of transcription 3-mediated suppression of apoptosis.
Rocchi P; Beraldi E; Ettinger S; Fazli L; Vessella RL; Nelson C; Gleave M
Cancer Res; 2005 Dec; 65(23):11083-93. PubMed ID: 16322258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
